Metis TechBio Co (7666) investor relations material

Executive summary

• Achieved operating revenue of RMB154.3 million for H1 2026, a 13,399% increase year-over-year, driven by major licensing and collaboration agreements.

• Adjusted net loss (non-IFRS) reduced by 56.4% to RMB51.1 million, reflecting improved operating efficiency and milestone payments.

• Significant progress in AI-driven platforms and expansion of the self-developed pipeline, with multiple candidates advancing in clinical and preclinical stages.

• Landmark global licensing deal for MTS-128 with Boulevard Bio, potential value over US$1.6 billion, and new collaborations with BioThunder AG, GenTurn Life, Edibeck, and Hengrui Pharma.

• Cash and equivalents, term deposits, and financial assets totaled RMB3,025.3 million, supporting a strong financial position.

Financial highlights

• Revenue from contracts with customers rose to RMB154.3 million from RMB1.14 million year-over-year, mainly from collaboration agreements.

• Gross profit increased to RMB153.1 million, with gross margin rising to 99.2%.

• R&D expenses increased by 48.1% to RMB172.4 million, reflecting continued investment in pipeline and technology.

• Administrative expenses rose 70.5% to RMB96.1 million; selling and marketing expenses up 365% to RMB21.3 million.

• Loss for the period narrowed by 20% to RMB153.2 million; adjusted net loss (non-IFRS) was RMB51.1 million.

• Net current assets reached RMB2,862.5 million; gearing ratio improved to 8.9% from 19.3%.

• Cash and cash equivalents: RMB2,527.3 million as of June 30, 2026.

• Net cash inflow from financing activities: RMB2,092.7 million, mainly from IPO/Global Offering.

Outlook and guidance

• Management expects to meet the revenue requirement for listing rules in 2027, supported by ongoing commercialization and strategic partnerships.

• Focus remains on advancing AI-driven life sciences, scaling Biological AI from molecular to cellular level, and expanding global collaborations.

• Long-term strategy targets cell reprogramming and end-to-end capabilities from molecular design to cell-fate regulation.